A newly identified group of bacteria called Rothia may hold the key to understanding why peanut allergies vary so dramatically from person to person. Researchers at McMaster University found that people with higher levels of these allergen-degrading bacteria can tolerate significantly more peanuts before experiencing a reaction, suggesting a potential pathway for future allergy treatments.

Why Do Some People Have Severe Peanut Allergies While Others Don't?

Peanut allergies affect 2% to 3% of Americans, making them one of the most common food allergies in North America. Yet the severity varies wildly. Some people experience life-threatening anaphylaxis from trace amounts, while others can eat small quantities without incident. Researchers wanted to understand what drives this difference.

The answer appears to lie in the oral and gut microbiome, the community of bacteria living in your mouth and digestive tract. A team led by Dr. Alberto Caminero Fernandez examined saliva and upper gut samples from healthy volunteers to identify which bacteria could break down peanut allergens. They discovered that Rothia species stood out as particularly effective at limiting how peanut proteins bind with antibodies, the process that triggers allergic reactions.

"We found evidence that some of these microbes may help break down peanut components in ways that could influence allergic responses. These findings point to a newly identified pathway linking the oral and gut microbiome with food allergy," said Dr. Alberto Caminero Fernandez, an associate professor of medicine at McMaster University.

Dr. Alberto Caminero Fernandez, Associate Professor of Medicine at McMaster University

The researchers validated their findings in a group of 120 children. Those with greater tolerance for peanuts had significantly more Rothia bacteria. These bacteria work by allowing fewer peanut allergens to reach the bloodstream and reducing activation of immune cells that cause anaphylaxis, resulting in much milder allergic reactions after exposure.

How Could This Research Lead to New Allergy Treatments?

The study, published in Cell Host and Microbe, opens several promising avenues for preventing and treating severe peanut allergies. Researchers identified specific mechanisms that could be targeted therapeutically, moving beyond the current standard of strict avoidance.

Potential approaches include:

• Microbial Therapies: Treatments designed to increase beneficial Rothia populations in the mouth and gut to naturally break down peanut allergens before they trigger immune responses.
• Probiotic Interventions: Targeted probiotic supplements containing Rothia or related species that could be taken to boost allergen-degrading bacteria in susceptible individuals.
• Oral Immunotherapies: Combined approaches that use the microbiome findings alongside existing oral immunotherapy techniques to help people gradually tolerate peanuts.

In Canada, where peanut allergy is the most common food allergy affecting children, strict avoidance remains the only recommended management strategy. However, about 1 in 3 kids experience accidental exposure each year, making new prevention and treatment options urgently needed.

The research team included collaborators from the United States and Spain, strengthening the international relevance of the findings. While these results are promising, researchers emphasize that more work is needed to translate laboratory discoveries into clinical treatments that can safely modify the microbiome and reduce allergy severity.

What Does This Mean for People With Peanut Allergies Today?

These findings do not immediately change how people should manage peanut allergies right now. Current medical guidance remains to avoid peanuts and carry emergency epinephrine auto-injectors if prescribed. However, the research provides hope that future therapies could offer alternatives to lifelong avoidance.

Understanding the microbiome's role in food allergies also highlights why individual responses to allergens differ so much. It is not simply about genetics or immune system strength; the specific bacterial populations colonizing your mouth and gut play a measurable role in determining how your body reacts to allergenic foods. This personalized perspective may eventually lead to tailored treatments based on each person's unique microbiome profile.